Brief reports
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia

https://doi.org/10.1016/j.amjcard.2004.09.015Get rights and content

In the 2-year Atorvastatin versus Simvastatin on Atherosclerosis Progression extension study, patients with familial hypercholesterolemia who continued to take atorvastatin 80 mg for an additional 2 years had complete arrest of the progression of mean carotid intima-media thickness (0.89 mm at the start vs 0.90 mm at the end of the study, p = 0.58). In contrast, patients previously taking simvastatin 40 mg had significant regression of intima-media thickness (0.95 mm at the start vs 0.92 mm at the end of the study, p = 0.01). Therefore, both placebo- and statin-treated patients with familial hypercholesterolemia are best treated with high-dose atorvastatin, a therapeutic regimen that induces atherosclerosis regression and is safe and well tolerated over a 4-year period.

References (8)

There are more references available in the full text version of this article.

Cited by (67)

  • Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial

    2017, Journal of Clinical Lipidology
    Citation Excerpt :

    One potential reason was that the greater use of statin therapy not only reduced atheroma volume, but also “stabilized” atherosclerotic plaques via reduced inflammation and increased collagen content,6 thus contributing to a lower baseline CIMT over time7,8 and greater challenges in producing differential CIMT and ASCVD outcomes benefits. For example, in trials using atorvastatin up to 80 mg/d, CIMT was often minimal, mitigating the potential of a lipid-altering agent to demonstrate a differential response of active treatment vs placebo.9–11 The results of these CIMT trials contrasted with the known benefits of atorvastatin demonstrated in cardiovascular outcome trials, including those in which patients were previously treated with lipid-lowering therapy.12

  • Combination therapy in dyslipidemia: Where are we now?

    2014, Atherosclerosis
    Citation Excerpt :

    This effect of atorvastatin was not evident either in studies of postmenopausal women [72,73], or in patients with FH treated with atorvastatin only in the Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor (RADIANCE) trial who had received substantial statin treatment prior to enrollment with a baseline CIMT of 0.68 and 0.72 mm, respectively [74]. However, in the Atorvastatin vs Simvastatin on Atherosclerosis Progression (ASAP) trial, atorvastatin 80 mg reduced CIMT in familial hypercholesterolemia (FH) patients who were untreated or not extensively treated with statins (CIMT 0.93 mm; LDL-C > 175 mg/dL) [75], although no further reduction of CIMT was seen in the 2-year extension of that study (0.89–0.90 mm) [76]. In the placebo-controlled Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) trial, rosuvastatin was associated with a statistically significant reduction in CIMT progression over 2 years and, although the study was not powered to make safety comparisons, no notable differences were seen in CVD event rates [77].

View all citing articles on Scopus

This study was supported by Pfizer, Capelle aan de Yssel, The Netherlands.

View full text